Press Room

Inhalation Anesthesia Market to exceed $1.6Bn by 2024

Inhalation Anesthesia Marketsize is set to exceed USD 1.6 billion by 2024; according to a new research report by Global Market Insights, Inc.

Rising number of geriatric population coupled with increasing number of chronic diseases such as cancer, cardiovascular, neurological, and respiratory disorders and introduction of advanced anesthesia will offer lucrative growth opportunities for the inhalation anesthesia market growth.

Increasing number of emergency surgeries driving the count of hospital admissions coupled with favorable private and public insurance will drive the inhalation anesthesia market. Growing investment in healthcare infrastructure development in emerging economies and increasing adoption of universal health coverage resulting in demand among public as well as private healthcare setups will propel the business growth.

Increasing number of surgeries performed in ambulatory surgical centers will stimulate business growth over the forecast years. Growing adoption of inhalation anesthesia for globally rising prevalence of cataract surgeries, enhanced access to healthcare treatments, and rise in disposable income will fuel the industry growth.

Adverse side effects during recovery, procedure or surgery, or wearing off anesthesia coupled with effect like intraoperative discomfort, hypotension, post-lumbar-puncture headache, and potential for neurologic and cardiac toxicity from anesthetics may hamper the inhalation anesthesia market growth.

Sevoflurane segment accounted for the highest revenue share in 2016 and will grow at a significant rate over the forecast period owing to growing use in both maintenance and induction. Isoflurane segment will grow at a significant rate pertaining to associated factors like systemic vessels expand and potentiates activities of muscle relaxants, preferred for neurosurgery, and sustained cardiac outputs will boost the business growth.

Maintenance accounted for highest revenue share of the application segment in 2016 and will grow at a significant rate over the forecast period owing to factors like safety of airway as nearly all patients that are anesthetized by means of these products are intubated. Increasing use in patients with low oxygen carrying capacities such as the patients with respirational dysfunction or anemia will fuel the segment growth in the coming years.

U.S. market was valued over USD 488 million in 2016 and will grow significantly over the coming years. Rising number of plastic surgeries and substantially increasing adoption rate of the process will drive the business growth in U.S. Furthermore, presence of associations that aids in maintaining the standards of anesthesiology will fuel the industry growth in the country.

Germany accounted for highest revenue share in the region, owing to increasing chronic conditions associated with elderly population coupled with adoption rate of inhalation anesthesia. Growing prevalence of cancers and cardiovascular disorders accounting for approximately 66% of overall deaths in Germany will drive the industry growth over the forecast years.

China will grow at a significant rate owing to its growing research studies in the business and high prevalence of lung cancer occurred due to pollution. Increasing use of sevoflurane and desflurane in general anesthesia pertaining to superiority of awakening afterwards surgical procedure as compared to traditional inhaled anesthetics will drive the industry growth in the country. Presence of organizations and associations offering platform for research and findings for anesthesia and mounting occurrence of chronic conditions will fuel the business growth in India.

Brazil is projected to grow at a substantial rate over the forecast period. Increasing prevalence of chronic conditions coupled with high adoption of inhalation anesthesia technique as compared to intravenous anesthesia (AVT) will stimulate business expansion in the country.

Some of the companies operating in market are Abbott, Baxter International, Piramal, Lunan Pharmaceutical, Hikma Pharmaceuticals and Halocarbon Products. Introduction of novel product and growing focus on geographical expansion will propel the industry growth. Key industry players will endeavor to reinforce their position in this competitive market by implementing these strategies.

Inhalation anesthesia market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2013 to 2024, for the following segments:

Inhalation anesthesia market by product

Sevoflurane

Desflurane

Isoflurane

Inhalation anesthesia market by application

Induction

Maintenance

The above information is provided for the following regions and countries: